173 related articles for article (PubMed ID: 15710455)
1. Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells.
Zhang Z; Weinschenk T; Schluesener HJ
J Neuroimmunol; 2005 Mar; 160(1-2):32-40. PubMed ID: 15710455
[TBL] [Abstract][Full Text] [Related]
2. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
Zhang Z; Guo K; Schluesener HJ
J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
[TBL] [Abstract][Full Text] [Related]
3. Binding and uptake of immunostimulatory CpG oligodeoxynucleotides by human neuroblastoma cells.
Guo LH; Schluesener HJ
Oligonucleotides; 2004; 14(4):287-98. PubMed ID: 15665596
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds.
Macfarlane DE; Manzel L
J Immunol; 1998 Feb; 160(3):1122-31. PubMed ID: 9570525
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer-like YT-INDY cells by oligodeoxynucleotides and binding by homologous pattern recognition proteins.
Kaur H; Jaso-Friedmann L; Leary JH; Praveen K; Brahmi Z; Evans DL
Scand J Immunol; 2005 Oct; 62(4):361-70. PubMed ID: 16253123
[TBL] [Abstract][Full Text] [Related]
6. siRNA binding proteins of microglial cells: PKR is an unanticipated ligand.
Zhang Z; Weinschenk T; Guo K; Schluesener HJ
J Cell Biochem; 2006 Apr; 97(6):1217-29. PubMed ID: 16315288
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies.
Manzel L; Strekowski L; Ismail FM; Smith JC; Macfarlane DE
J Pharmacol Exp Ther; 1999 Dec; 291(3):1337-47. PubMed ID: 10565859
[TBL] [Abstract][Full Text] [Related]
8. Pigpen is a cellular binding protein of therapeutic oligonucleotides.
Zhang Z; Schluesener HJ
Cytotherapy; 2005; 7(2):186-94. PubMed ID: 16040398
[TBL] [Abstract][Full Text] [Related]
9. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.
Heikenwalder M; Polymenidou M; Junt T; Sigurdson C; Wagner H; Akira S; Zinkernagel R; Aguzzi A
Nat Med; 2004 Feb; 10(2):187-92. PubMed ID: 14745443
[TBL] [Abstract][Full Text] [Related]
10. CpG-ODN increases resistance of olive flounder (Paralichthys olivaceus) against Philasterides dicentrarchi (Ciliophora: Scuticociliatia) infection.
Lee EH; Kim KH
Fish Shellfish Immunol; 2009 Jan; 26(1):29-32. PubMed ID: 18992348
[TBL] [Abstract][Full Text] [Related]
11. Uptake, cellular distribution and novel cellular binding proteins of immunostimulatory CpG oligodeoxynucleotides in glioblastoma cells.
Zhang Z; Weinschenk T; Schluesener HJ
Mol Cell Biochem; 2005 Apr; 272(1-2):35-46. PubMed ID: 16010970
[TBL] [Abstract][Full Text] [Related]
12. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides.
Matsuoka N; Nishikawa M; Mohri K; Rattanakiat S; Takakura Y
J Control Release; 2010 Dec; 148(3):311-6. PubMed ID: 20887761
[TBL] [Abstract][Full Text] [Related]
13. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
[TBL] [Abstract][Full Text] [Related]
14. Decreased intracellular TLR9 confers hyporesponsiveness of RAW264.7 cells to subsequent CpG ODN challenge.
Wei L; Hong Z; Jiang Z; Guofu D; Hongwei C; Liangxi W; Yongling L; Bin L; Ping L
Int Immunopharmacol; 2006 Jun; 6(6):935-46. PubMed ID: 16644479
[TBL] [Abstract][Full Text] [Related]
15. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury, but provide a late window for protection against endotoxin-mediated liver damage.
Slotta JE; Scheuer C; Menger MD; Vollmar B
J Hepatol; 2006 Mar; 44(3):576-85. PubMed ID: 16310279
[TBL] [Abstract][Full Text] [Related]
17. In vivo immunostimulatory effects of CpG ODN in newborn piglets.
Linghua Z; Xingshan T; Fengzhen Z
Mol Immunol; 2007 Feb; 44(6):1238-44. PubMed ID: 16908068
[TBL] [Abstract][Full Text] [Related]
18. Phosphorothioate backbone modification modulates macrophage activation by CpG DNA.
Sester DP; Naik S; Beasley SJ; Hume DA; Stacey KJ
J Immunol; 2000 Oct; 165(8):4165-73. PubMed ID: 11035048
[TBL] [Abstract][Full Text] [Related]
19. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells.
Britigan BE; Lewis TS; Waldschmidt M; McCormick ML; Krieg AM
J Immunol; 2001 Sep; 167(5):2921-8. PubMed ID: 11509640
[TBL] [Abstract][Full Text] [Related]
20. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
Zimmermann S; Dalpke A; Heeg K
Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
